MORE BAV.. DATA DUE OUT, AND THIS WON'T BE ALMOST IMPOSSIBLE TO TREAT PANCREATIC CANCER.
YEP. ANY DAY NOW THIS COULD OPEN AT $3 PUS SHORTY WHAT YA GOING TO have Fruadsetin write another =expose on himself! as a blundering liar and moron---placebo extnded lives for SCLC??? no way. it was the bavi!!
Regarding the .21 p value for MOS in a phase 2 NSCLC study...does anyone know of a similar phase 2 study that did show a significant difference in MOS? B/c the study you mention has objective response rate as its primary endpoint- data that have yet to be disclosed. If you could cite a phase 2 NSCLC study that displayed sig differences in MOS, I will thank you for it